Immunotherapy for esophageal squamous cell carcinoma: a review

• Mimura Kosaku

  Department of Gastrointestinal Tract Surgery, Fukushima Medical University Department of Advanced Cancer Immunotherapy, Fukushima Medical University Department of Progressive DOHaD Research, Fukushima Medical University

• Yamada Leo

  Department of Gastrointestinal Tract Surgery, Fukushima Medical University

• Ujiie Daisuke

  Department of Gastrointestinal Tract Surgery, Fukushima Medical University

• Hayase Suguru

  Department of Gastrointestinal Tract Surgery, Fukushima Medical University

• Tada Takeshi

  Department of Gastrointestinal Tract Surgery, Fukushima Medical University

• Hanayama Hiroyuki

  Department of Gastrointestinal Tract Surgery, Fukushima Medical University

• Thar Min Aung Kyi

  Department of Gastrointestinal Tract Surgery, Fukushima Medical University

• Shibata Masahiko

  Department of Gastrointestinal Tract Surgery, Fukushima Medical University Department of Advanced Cancer Immunotherapy, Fukushima Medical University

• Momma Tomoyuki

  Department of Gastrointestinal Tract Surgery, Fukushima Medical University

• Saze Zenichiro

  Department of Gastrointestinal Tract Surgery, Fukushima Medical University

• Ohki Shinji

  Department of Gastrointestinal Tract Surgery, Fukushima Medical University

• Kono Koji

  Department of Gastrointestinal Tract Surgery, Fukushima Medical University

Abstract

Cancer vaccines and immune checkpoint inhibitors (ICI) have recently been employed as immunotherapies for esophageal squamous cell carcinoma (ESCC). Cancer vaccines for ESCC have yielded several promising results from investigator-initiated phase I and II clinical trials. Furthermore, a Randomized Controlled Trial as an adjuvant setting after curative surgery is in progress in Japan. On the other hand, ICI, anti-CTLA-4 mAb and anti-PD-1 mAb, have demonstrated tumor shrinkage and improved overall survival in patients with multiple cancer types. For ESCC, several clinical trials using anti-PD-1/anti-PD-L1 mAb are underway with several recent promising results. In this review, cancer vaccines and ICI are discussed as novel therapeutic strategies for ESCC.

Journal

• FUKUSHIMA JOURNAL OF MEDICAL SCIENCE

  FUKUSHIMA JOURNAL OF MEDICAL SCIENCE 64 (2), 46-53, 2018

  THE FUKUSHIMA SOCIETY OF MEDICAL SCIENCE

Keywords

• esophageal squamous cell carcinoma
• immunotherapy
• cancer vaccine
• immune checkpoint inhibitors

Details

• CRID: 1390282763039228288
• NII Article ID: 130007471687
• NII Book ID: AA0065246X
• DOI: 10.5387/fms.2018-09
• ISSN: 21854610
• ISSN: 00162590
• PubMed: 30058598
• Web Site: http://ir.fmu.ac.jp/dspace/handle/123456789/693
• Web Site: https://www.jstage.jst.go.jp/article/fms/64/2/64_2018-09/_pdf
• Text Lang: en
• Data Source:
  • JaLC
  • IRDB
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed